Handling rescue therapy in myasthenia gravis clinical trials: why it matters and why you should care
Abstract Myasthenia gravis (MG) clinical trials typically allow rescue therapy during follow‐up in the event of marked worsening of MG symptoms. Failure to appropriately address rescue therapy in defining treatment effects and planning statistical analyses may yield biased estimates, increase false positive rates, or decrease statistical power – all of
Justin M. Leach+3 more
wiley +1 more source
Phytogenic Feed Additives as a Sustainable Alternative to Antibiotics: Enhancing Growth and Disease Resistance in Nile Tilapia (Oreochromis niloticus). [PDF]
Gruber C+3 more
europepmc +1 more source
Universal Proteomic Signature After Exercise‐Induced Muscle Injury in Muscular Dystrophies
ABSTRACT Objective Several neuromuscular disorders (NMDs) are characterized by progressive muscle damage and are marked by the elevation of circulating muscle proteins from activity‐related injury. Despite a diverse array of genetic drivers, many NMDs share similar patterns of exercise intolerance and higher concentrations of muscle injury proteins ...
Mads G. Stemmerik+5 more
wiley +1 more source
The receptor MIK2 interacts with the kinase RKS1 to control quantitative disease resistance to Xanthomonas campestris. [PDF]
Delplace F+3 more
europepmc +1 more source
Epitope Mapping of Anti‐Neurofascin 155 Antibody in a Large Cohort of Autoimmune Nodopathy Patients
ABSTRACT Objective Autoimmune nodopathy (AN), a newly recognized disease entity, is an immune‐mediated polyneuropathy involving autoantibodies against cell adhesion molecules located in nodes of Ranvier and paranodal regions, such as neurofascin 186 (NF186) and neurofascin 155 (NF155). The present study aimed to identify the epitopes for autoantibodies
Amina A. Abdelhadi+6 more
wiley +1 more source
Genetic engineering, including genome editing, for enhancing broad-spectrum disease resistance in crops. [PDF]
Han X+11 more
europepmc +1 more source
ABSTRACT Background and Objectives Ofatumumab, a fully human anti‐CD20 monoclonal antibody, is effective in reducing relapses and disability progression in patients with multiple sclerosis. This study aimed to examine immune profile changes associated with ofatumumab in a prospective cohort of Chinese patients with relapsing–remitting multiple ...
Shu Yang+9 more
wiley +1 more source
Phased T2T genome assemblies facilitate the mining of disease-resistance genes in Vitis davidii. [PDF]
Luo Y+18 more
europepmc +1 more source